Cas No.Product NameDescription
1207456-01-6BMN673BMN-673 is an orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential antineoplastic activity.
912444-00-9VeliparibVeliparib is a potent inhibitor of both PARP-1 and PARP-2 by [3H]NAD+ with Kis of 5.2 and 2.9 nmol/L, respectively.
459868-92-9Rucaparib phosphateRucaparib (inhibit parp), ki value at 1.4 nm.
160003-66-7IniparibBSI-201(Iniparib) is a potent PARP1 inhibitor with strong anti-neoplastic effect.
763113-22-0olaparidOlaparib (AZD2281) is a potent PARP inhibitor with IC50 of 5 and 1 nM for PARP-1and PARP-2, respectively.
934162-61-5A-966492A-966492 is one of the most potent PARP inhibitors.
328543-09-5AG14361AG14361 is a potent poly(ADP-ribose) polymerase (PARP-1) inhibitor with a GI50 of 10.9 μM.
1268524-70-4(+)-JQ-1 JQ1 displaces BET proteins from chromatin by competitively binding to the acetyl-lysine recognition pocket of BET bromodomains.
1446144-04-2CPI-203CPI203 is a novel potent, selective and cell permeable inhibitor of the bromodomain and extra terminal (BET) family protein BRD4 with an IC50 of ~37 nM (BRD4 α-screen assay).
1044870-39-4RVX-208RVX-208 is a first-in-class, small molecule that inhibits BET bromodomains.
344458-19-1PJ-34PJ34 (hydrochloride) is a novel potent specific inhibitor of PARP-l. PJ34 has been reported to enhance chemotherapeutic effects in certain types of tumors.
108409-83-2FH535FH535 is a compound that suppresses both Wnt/beta-catenin and peroxisome proliferator-activated receptor (PPAR) signaling.
832714-46-2APD668APD668 is a potent GPR119 agonist with EC50 of 2.7 nM and 33 nM for hGPR119 and ratGPR119 respectively.
1446144-04-2CPI203CPI 203 is a novel potent, selective and cell permeable inhibitor of the bromodomain and extra terminal (BET) family protein BRD4 with an IC50 of ~37 nM (BRD4 α-screen assay).
244240-24-2LFM-A13LFM-A13 is a potent and selective inhibitor of Btk with IC50 of 17.2 uM; also inhibits PLK3 with IC50 of 7.2 uM.
1619994-68-1GSK-2801GSK2801 is a potent, selective and cell active acetyl-lysine competitive inhibitor of BAZ2A(Kd=136 nM) and BAZ2B(Kd=257 nM) bromodomains.
1038915-73-9MK-4827 tosylateNiraparib, also known as MK4827, is an orally active, potent and selective poly(ADP-Ribose) polymerase (PARP) inhibitor that radiosensitizes human lung and breast cancer cells. Niraparib inhibits PARP1/PARP2 with IC50 of 3.8 nM/2.1 nM respectively. Niraparib is currently in Phase 3 clinical trials for ovarian cancer and BRCA+ breast cancer.
1439901-97-9ONO-4059 hydrochlorideONO-4059 is a selective and novel inhibitor of BTK with IC50 2.2 nm, ONO-4059 binds to BTK within B cells, thereby preventing B-cell receptor signaling and impeding B-cell development.
1038915-64-8MK-4827 hydrochlorideMK-4827(Niraparib) Hcl is a selective inhibitor of PARP1/PARP2 with IC50 of 3.8 nM/2.1 nM; with great activity in cancer cells with mutant BRCA-1 and BRCA-2; >330-fold selective against PARP3, V-PARP and Tank1.
1351636-18-4ONO-4059ONO-4059 is a highly selective, orally bioavailable BTK inhibitor with a potency (IC50) of 2.2 nM.

First Previous Next End   Jump to  Page
Cell Cycle/Checkpoint
Angiogenesis/Tyrosine Kinase
Apoptosis Pathway
Aurora/Ksp Pathway
MAPK Pathway
Hormone Pathay
Proteases/HSP90/HSP70 Pathway
Wnt/Hedgehog/Notch Pathway
Jak/Stat Pathway
Ca/cAMP/Lipid Signaling Pathway
Neuro Signaling Pathway
TGF-beta/Smad Signaling Pathway
GPCR Pathway
Ion channel Pathway
Cytochrome P450 Pathway
Others Pathway